TY - JOUR
T1 - Responses to ragweed-pollen nasal challenge before and after immunotherapy
AU - Creticos, Peter S.
AU - Marsh, David G.
AU - Proud, David
AU - Kagey-Sobotka, Anne
AU - Adkinson, N. Franklin
AU - Friedhoff, Linda
AU - Naclerio, Robert M.
AU - Lichtenstein, Lawrence M.
AU - Norman, Philip S.
N1 - Funding Information:
From the Clinical Immunology Division, Department of Medicine, The Johns Hopkins University and the Good Samaritan Hospital, Baltimore, Md. Supported by National Institutes of Health Grants AI 04866, AI 08270, and NS 22488. Received for publication Nov. 9, 1988. Revised Feb. 22, 1989. Accepted March 22, 1989. Reprint requests: Peter S. Creticos, MD, Clinical Immunology Di-vision, The Johns Hopkins University at The Good Samaritan Hospital, 5601 Loch Raven Blvd., Baltimore, MD 21239. Publication No. 757 from the O’Neill Laboratories of The Good Samaritan Hospital, Baltimore, Md. *Recipient of a Teacher Investigator Development Award NS 008 I 1 from the National Institute of Neurologic and Communicative Disorders and Stroke.
PY - 1989/8
Y1 - 1989/8
N2 - To evaluate whether immunotherapy reduces mediator release after nasal challenge, we followed previously untreated patients with ragweed hay fever through 2 years (three seasons) of treatment. Eleven adult patients started immunotherapy after a season of symptom diaries and graded pretreatment challenges with 0.03, 0.3, 3.3, and 16.5 mg of ragweed pollen. Repeat challenges were performed when the treatment dosage reached 0.6, 12.4, and 24.8 μg of Amb a I (antigen E) equivalents per injection. After the 0.6 μg dose, there was little change, but after the larger doses, there was a significant reduction in histamine and tosylarginine methyl ester-esterase (TAME-esterase) release in two respects. More pollen was required before any mediator appeared, and the amount of mediator released at each stage of the challenge was reduced. There was no significant difference between the responses at the 12.4 and 24.8 μg treatment doses. Sneezing after challenge was not apparently changed after immunotherapy; however, patients' seasonal symptom-medication scores were reduced after treatment. These data set the optimal individual treatment dose of ragweed extract for immunotherapy at >0.6 μg, but probably not more than 12.4 μg in terms of Amb a I equivalents.
AB - To evaluate whether immunotherapy reduces mediator release after nasal challenge, we followed previously untreated patients with ragweed hay fever through 2 years (three seasons) of treatment. Eleven adult patients started immunotherapy after a season of symptom diaries and graded pretreatment challenges with 0.03, 0.3, 3.3, and 16.5 mg of ragweed pollen. Repeat challenges were performed when the treatment dosage reached 0.6, 12.4, and 24.8 μg of Amb a I (antigen E) equivalents per injection. After the 0.6 μg dose, there was little change, but after the larger doses, there was a significant reduction in histamine and tosylarginine methyl ester-esterase (TAME-esterase) release in two respects. More pollen was required before any mediator appeared, and the amount of mediator released at each stage of the challenge was reduced. There was no significant difference between the responses at the 12.4 and 24.8 μg treatment doses. Sneezing after challenge was not apparently changed after immunotherapy; however, patients' seasonal symptom-medication scores were reduced after treatment. These data set the optimal individual treatment dose of ragweed extract for immunotherapy at >0.6 μg, but probably not more than 12.4 μg in terms of Amb a I equivalents.
UR - http://www.scopus.com/inward/record.url?scp=0024433538&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024433538&partnerID=8YFLogxK
U2 - 10.1016/0091-6749(89)90325-4
DO - 10.1016/0091-6749(89)90325-4
M3 - Article
C2 - 2668381
AN - SCOPUS:0024433538
SN - 0091-6749
VL - 84
SP - 197
EP - 205
JO - The Journal of allergy and clinical immunology
JF - The Journal of allergy and clinical immunology
IS - 2
ER -